A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

NCT04356846 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: LP-108 tablet

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]
[object Object]